ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models.
Open access · goldAbstract read
In one paragraph
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 19 citations in OpenAlex.
- An Engineered HR1-Stem Helix-HR2 Trimeric Platform for Developing Broad-Spectrum Coronavirus Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- The first key for the Priority Pathogens: Protective immunogens in development of vaccines and medications.Biosafety and health · 2026Review
- Rational design of an optimized ferritin nanoparticle vaccine targeting both SARS-CoV-2 and MERS-CoV.Journal of nanobiotechnology · 2026Article
- An mRNA Vaccine with Tandem Mutated HA-NA Confers Protection Against Multiple Strains of H1N1 Influenza.Vaccines · 2026Article
- Dual induction of tissue-resident T and B cell immunity for broad influenza protection with a nanofiber-VLP vaccine.Journal of nanobiotechnology · 2026Article
- From Innate to Adaptive: Paradigm Shifts and Frontier Challenges in Next-Generation Vaccine Design.Vaccines · 2026Review
- Universal broad-spectrum mucosal vaccine design for human coronaviruses inspired by artificial antibodies.NPJ vaccines · 2026Article
- Development of a Thermostable and Broadly Neutralizing Pan-Sarbecovirus Vaccine Candidate.ACS infectious diseases · 2026Article
- Trivalent coronavirus vaccines elicit broad-spectrum immunity in mice and attenuate respiratory viral load in golden hamsters.Frontiers in immunology · 2026Article
- SARS-CoV-2 RBD Scaffolded by AP205 or TIP60 Nanoparticles and Delivered as mRNA Elicits Robust Neutralizing Antibody Responses.Vaccines · 2025Article
- An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.NPJ vaccines · 2025Article
- Article
- Adenovirus Nanoparticles Displaying RBD Induce a Protective Immune Response Against BA.5 in Mice.International journal of nanomedicine · 2025Article
- Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.Cell reports · 2024Article
- Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.Journal of virology · 2024Article
- Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.bioRxiv : the preprint server for biology · 2024Article
- Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Designed mosaic nanoparticles enhance cross-reactive immune responses in mice.bioRxiv : the preprint server for biology · 2024Article
- Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 2 countries.
Yanjun ZhangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Jing SunState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Jian ZhengDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, 52242, USA.
Suxiang LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Haiyue RaoState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Jun DaiGuangzhou Customs District Technology Center, Guangzhou, 510700, P. R. China.
Zhaoyong ZhangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Yanqun WangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Donglan LiuState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Zhao ChenState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Wei RanState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Airu ZhuState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Fang LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Qihong YanState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Yiliang WangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Kuai YuState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Shengnan ZhangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Dong WangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Yanhong TangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Banghui LiuState Key Laboratory of Respiratory Disease, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, P. R. China.
Linling ChengState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Jiandong HuoState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Stanley PerlmanDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, 52242, USA.
Jingxian ZhaoState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.
Jincun ZhaoState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510300, P. R. China.ORCID 0000-0003-2515-5589
First Affiliated Hospital of Guangzhou Medical University · CNSouthern University of Science and Technology · CNUniversity of Iowa · USChinese Academy of Sciences · CNGuangzhou Experimental Station · CNShanghai Customs College · CN
Funding
SARS-CoV Proteins in Heterologous Viral InfectionP01AI060699 · NIAID · UNIVERSITY OF IOWA · PI PERLMAN, STANLEY · 2004 to 2021
$21.5MRole of eicosanoids in pathogenic human CoV infectionsR01AI129269 · NIAID · UNIVERSITY OF IOWA · PI Stanley Perlman · 2016 to 2026
$4.7MBasic and Applied Basic Research Foundation of Guangdong ProvinceGuangdong Basic and Applied Basic Research Foundation 2019B1515120068 JCZGuangdong Basic and Applied Basic Research Foundation 2021A1111100009 JDGuangdong Basic and Applied Basic Research Foundation 2021B1212030016 JDGuangdong Basic and Applied Basic Research Foundation 2021B1515130005 JXZGuangdong Basic and Applied Basic Research Foundation 2022B1515020059Guangdong Basic and Applied Basic Research Foundation 2022B1515020059 JSGuangdong Basic and Applied Basic Research Foundation 2023B1515020040 YWGuangdong Medical Research Foundation ZNSA-2020013Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through Animal Disease Management Technology Advancement Support Program, funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) 122012-2Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through Animal Disease Management Technology Advancement Support Program, funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) 122060-2National Key R&D Program of China 2021YFC2301700 CFNational Natural Science Foundation of China 82001750 YZNational Natural Science Foundation of China 82025001 JZNational Natural Science Foundation of China 82170003 LCNational Natural Science Foundation of China 82172240 YWNIAID NIH HHS P01 AI060699NIAID NIH HHS R01 AI129269
Abstract
To combat SARS-CoV-2 variants and MERS-CoV, as well as the potential re-emergence of SARS-CoV and spillovers of sarbecoviruses, which pose a significant threat to global public health, vaccines that can confer broad-spectrum protection against betacoronaviruses (β-CoVs) are urgently needed. A mosaic ferritin nanoparticle vaccine is developed that co-displays the spike receptor-binding domains of SARS-CoV, MERS-CoV, and SARS-CoV-2 Wild-type (WT) strain and evaluated its immunogenicity and protective efficacy in mice and nonhuman primates. A low dose of 10 µg administered at a 21-day interval induced a Th1-biased immune response in mice and elicited robust cross-reactive neutralizing antibody responses against a variety of β-CoVs, including a series of SARS-CoV-2 variants. It is also able to effectively protect against challenges of SARS-CoV, MERS-CoV, and SARS-CoV-2 variants in not only young mice but also the more vulnerable mice through induction of long-lived immunity. Together, these results suggest that this mosaic 3-RBD nanoparticle has the potential to be developed as a pan-β-CoV vaccine.
Indexed as
Coronavirus InfectionsMiddle East Respiratory Syndrome CoronavirusNanoparticlesViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralHumansMiceModels, AnimalSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralViral Vaccinesmosaic RBD nanoparticle vaccine coronavirus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.